MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

This study has been terminated.
(CSR is complete. Study is now closed.)
Information provided by (Responsible Party):
Amgen Identifier:
First received: April 12, 2007
Last updated: July 13, 2015
Last verified: July 2015

To determine if treatment with AMG 706 in combination with paclitaxel and carboplatin improves overall survival compared to treatment with placebo in combination with paclitaxel and carboplatin in subjects with advanced non-squamous NSCLC and in subjects with adenocarcinoma histology (adenocarcinoma subpopulation).

Condition Intervention Phase
Non-Small Cell Lung Cancer
Drug: AMG 706
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer.

Resource links provided by NLM:

Further study details as provided by Amgen:

Primary Outcome Measures:
  • Overall survival time. Time from randomization to death. Subjects who have not died while on study or are lost to follow up will be censored at their last contact date. [ Time Frame: Not able to be measured ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Duration of response (calculated for only those subjects who respond) [ Time Frame: Time from first objective tumour response to objective disease progression or death due to any cause. ] [ Designated as safety issue: No ]
  • Pharmacokinetics of AMG 706 when administered in combination with paclitaxel and carboplatin. [ Time Frame: Throughout the duration the patient is in the study. ] [ Designated as safety issue: No ]
  • Association of AMG 706 treatment-induced PlGF increase with OS in subjects with non-squamous NSCLC and in subjects with adenocarcinoma histology [ Time Frame: Overall survival time in the PlGF analysis set ] [ Designated as safety issue: No ]
  • Evaluation of OS, PFS, AMG 706 treatment-induced PlGF increase association with OS, ORR (only in subjects with measurable disease) and duration of response in subjects with non-squamous, non-adenocarcinoma histology [ Time Frame: OS, ORR and duration of response in the PlGF analysis set ] [ Designated as safety issue: No ]
  • Evaluation of the pharmacokinetics of AMG 706 and metabolites when administered with paclitaxel and carboplatin (in approximately 250 subjects at selected centers) [ Time Frame: Carboplatin PK samples drawn from subjects at Cycle 3 and Cycle 5 ] [ Designated as safety issue: No ]
  • Safety and tolerability of AMG 706 in combination with paclitaxel and carboplatin compared to placebo in combination with paclitaxel and carboplatin in subjects with non-squamous NSCLC histology and in subjects with adenocarcinoma histology. [ Time Frame: Throughout the duration the patient is in the study ] [ Designated as safety issue: Yes ]
  • Progression free survival time: Subjects who have not progressed or died on study will be censored at their last evaluable assessment date. [ Time Frame: Time from randomization to objective disease progression or death due to any cause ] [ Designated as safety issue: No ]
  • Objective tumour response rate (complete and partial response) according to modified RECIST criteria in subjects with measurable disease at baseline. [ Designated as safety issue: No ]

Enrollment: 1450
Study Start Date: July 2007
Study Completion Date: August 2013
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Arm B
All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and placebo 125mg QD orally
Drug: placebo
125 mg QD orally every day
Active Comparator: Arm A
All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and AMG 706 125mg QD orally.
Drug: AMG 706
125 mg QD orally every day


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed, unresectable stage 111B with pericardial or pleural effusion or stage IV or recurrent non squamous NSCLC.
  • Measurable or non-measurable disease per modified RECIST criteria
  • ECOG performance status of 0 or 1
  • Life expectancy of greater than or equal to 3 months as documented by the investigator
  • ability to take oral medications
  • competency to give written informed consent
  • able to start protocol directed therapy within 7 days from date of randomization
  • Hematological function, as follows:
  • Absolute neutrophil count (ANC) > = 1.5 x 109/L
  • Platelet count > = 100 x 109/L and < = 850 x 109/L
  • Hemoglobin > =9 g/dL
  • Renal function, as follows:
  • Creatinine clearance > 40 mL/min (calculated by Cockcroft Gault formula)
  • Urinary protein quantitative value of < = 30 mg in urinalysis or < = 1+ on dipstick unless quantitative protein is < 500 mg in a 24 hour urine sample
  • Hepatic function, as follows:
  • Aspartate aminotransferase (AST) < =2.5 x upper limit of normal (ULN) OR AST < 5 x ULN if liver metastases are present
  • Alanine aminotransferase (ALT) < =2.5 x ULN OR ALT < 5 x ULN if liver metastases are present
  • Alkaline phosphatase < = 2.0 x ULN OR alkaline phosphatase < 5 x ULN if liver or bone metastases are present
  • Total bilirubin < 1.5 x ULN OR total bilirubin < 3 X ULN if subject has UGT1A1 promoter polymorphism (ie, Gilbert syndrome) confirmed by genotyping or Invader UGT1A1 Molecular Assay prior to randomization Partial thromboplastin (PTT) or activated partial thromboplastin time (aPTT) < = 1 x ULN and international normalized ratio (INR) < = 1.5 x ULN

Exclusion Criteria:

  • Subjects with adenosquamous histology or an unclear histology subtype (eg, not otherwise specified) containing greater than 10% squamous cells
  • untreated or symptomatic central nervous system metastases. Subjects with a history of brain metastases are eligible if definitive therapy has been administered (surgery and/or radiation therapy), there is no planned treatment for brain metastases, and the subject is clinically stable and is off corticosteroids for at least 2 weeks prior to randomization.
  • Prior chemotherapy as follows: Any prior chemotherapy for advanced non squamous NSCLC
  • Any prior adjuvant chemotherapy for non squamous NSCLC within 52 weeks prior to randomization. Adjuvant chemotherapy completed > 52 weeks prior to randomization is permitted. Any prior chemoradiation for locally advanced stage III disease.
  • Prior (within 30 days of randomization) yellow fever vaccination.
  • Central (chest) radiation therapy within 28 days prior to randomization, radiation therapy within 14 days prior to randomization for peripheral lesions.
  • History of pulmonary hemorrhage or gross hemoptysis (approximately 3 mL of bright red blood or more) within 6 months prior to randomization.
  • Prior targeted therapies, including but not limited to:
  • AMG 706, inhibitors of VEGF (eg, SU5416, SU6668, ZD6474, SU11248, PTK787, AZD2171, AEE 788, sorafenib, bevacizumab), or EGFr (eg, panitumumab, cetuximab, gefitinib, erlotinib).
  • Known history of allergy or hypersensitivity reaction to paclitaxel or carboplatin.
  • Any anticoagulation therapy within 7 days prior to randomization. The use of low-dose warfarin [ < = 2 mg daily] or low molecular weight heparin or heparin flushes for prophylaxis against central venous catheter thrombosis is allowed.
  • History of arterial or venous thrombosis within 12 months prior to randomization.
  • History of bleeding diathesis or bleeding within 14 days prior to randomization.
  • Peripheral neuropathy > grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
  • Clinically significant cardiac disease within 12 months of randomization, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, percutaneous transluminal coronary angioplasty/stent, congestive heart failure, or ongoing arrhythmias requiring medication.
  • History of other primary cancer unless: Curatively resected non melanomatous skin cancer. Curatively treated cervical carcinoma in situ. Other primary solid tumor curatively treated with no known active disease present and no curative treatment administered for the last 3 years
  • Any kind of disorder that compromises the ability of the subject to comply with the study procedures.
  • Open wound, ulcer or fracture.
  • Uncontrolled hypertension as defined by resting blood pressure > 150/90 mm Hg. Antihypertensive medications are allowed if the subject is stable on their current dose at the time of randomization.
  • Surgery:
  • Major surgical procedures within 28 days prior to randomization
  • Minor surgical procedures within 14 days prior to randomization
  • Failure to recover from prior surgery
  • Placement of a central venous access device (including ports and tunneled or non-tunneled catheters) within 7 days prior to randomization
  • Planned elective surgery while on study treatment
  • Core needle biopsy within 7 days prior to randomization
  • Not recovered from all previous therapies (ie, radiation, surgery and medications). Adverse events related to previous therapies must be CTCAE grade < = 1 at screening or returned to the subject's baseline prior to their most recent previous therapy.
  • Participation in therapeutic clinical trials or currently receiving other investigational treatment(s) within 30 days prior to randomization.
  • Pregnant (eg, positive HCG test-serum or urine) or breast feeding woman.
  • Any subject not consenting to use adequate contraceptive precautions (eg, hormonal, barrier or abstinence) during the course of the study and for 6 months after the last treatment.
  • Known to be human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C positive.
  • Known chronic hepatitis.
  • Active infection requiring systemic treatment or any uncontrolled infection < = 14 days prior to randomization.
  • History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with the study participation or investigational product(s) administration or may interfere with the interpretation of the results.
  • Previously randomized to this study.
  • Not available for follow-up assessments or unable to comply with study requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00460317

Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Amgen Identifier: NCT00460317     History of Changes
Other Study ID Numbers: 20050201
Study First Received: April 12, 2007
Last Updated: July 13, 2015
Health Authority: South Korea: Korea Food & Drug Administration
Spain: Spanish Drug Agency
Taiwan: Taiwan Provincial Department of Health
Turkey: Ministry of Health
Ukraine: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration
Austria: Secretariat of Health
Brazil: Ministry of Health
Canada: Health Canada
Chile: Health Ministry
Czech Republic: State Institute for Drug Control
Denmark: Danish Medicines Agency
France: Ministry of Health
Germany: Federal Institute for Drugs and Medical Devices
Greece: National Organization for Medicines
Hong Kong: Department of Health
Argentina: Ministry of Health
Australia: Therapeutic Goods Administration
Hungary: National Institute of Pharmacy
India: Central Drugs Standard Control Organization
Ireland: Irish Medicines Board
Israel: Ministry of Health
Italy: Ministry of Health
Lithuania: State Medicines Control Agency of Lithuania
Mexico: Ministry of Health
Netherlands: Medicines Evaluation Board
Phillippines: the Bureau of Food and Drugs
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Russia: Ministry of Health
Singapore: Health Science Authority
Slovakia: Ministry of Health

Keywords provided by Amgen:
multi kinase inhibitor

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Lung Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators processed this record on September 03, 2015